Stress Urinary Incontinence Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034
The 7 major stress urinary incontinence markets are expected to exhibit a CAGR of 6.14% during 2024-2034.
The stress urinary incontinence market has been comprehensively analyzed in IMARC's new report titled "Stress Urinary Incontinence Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Stress urinary incontinence is a common condition characterized by the unintentional leakage of urine during activities that put pressure on the bladder. It occurs when the muscles and tissues that support the bladder and control the release of urine become weakened or damaged. The condition is more prevalent in women, especially those who have gone through pregnancy and childbirth, but it can also affect men. The primary symptom of the ailment is the unintentional leakage of urine, which can range from a few drops to a significant amount. Diagnosing stress urinary incontinence involves a comprehensive evaluation by a healthcare professional. The diagnostic process typically includes a thorough medical history and physical examination, where the healthcare provider may assess pelvic floor muscle strength and perform tests to reproduce SUI symptoms. Additional diagnostic procedures, such as urodynamic testing, which evaluates bladder function and measures the amount of urine leakage during various activities, may be conducted. Numerous other tests may include urine analysis to rule out infections and imaging studies to evaluate the urinary tract and pelvic organs.
The increasing cases of vaginal delivery, which can stretch and damage pelvic floor muscles, thereby compromising their ability to provide adequate support to the bladder and urethra, are primarily driving the stress urinary incontinence market. Apart from this, the rising incidences of various associated risk factors, including hormonal changes, chronic coughing, lack of regular exercise, certain connective tissue disorders like Ehlers-Danlos syndrome, prior pelvic surgery, participation in high-impact activities, etc., are also bolstering the market growth. Furthermore, the widespread adoption of estrogen creams to restore the tissue health and elasticity of the urethral tissues as well as reduce urine leakage is creating a positive outlook for the market. Besides this, the escalating utilization of pelvic floor physical therapy, which uses a variety of strategies, including manual therapy, biofeedback, electrical stimulation, etc., to help patients regain control over their pelvic floor muscles and alleviate disease symptoms, is also augmenting the market growth. Additionally, the emerging popularity of neuromodulation techniques, such as sacral nerve stimulation (SNS) and percutaneous tibial nerve stimulation (PTNS), for modulating neural signals and improving urinary control is expected to drive the stress urinary incontinence market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the stress urinary incontinence market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for stress urinary incontinence and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the stress urinary incontinence market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the stress urinary incontinence market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the stress urinary incontinence market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current stress urinary incontinence marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the stress urinary incontinence market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the stress urinary incontinence market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the stress urinary incontinence market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of stress urinary incontinence across the seven major markets?
What is the number of prevalent cases (2018-2034) of stress urinary incontinence by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of stress urinary incontinence by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with stress urinary incontinence across the seven major markets?
What is the size of the stress urinary incontinence patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of stress urinary incontinence?
What will be the growth rate of patients across the seven major markets?
Stress Urinary Incontinence: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for stress urinary incontinence drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the stress urinary incontinence market?
What are the key regulatory events related to the stress urinary incontinence market?
What is the structure of clinical trial landscape by status related to the stress urinary incontinence market?
What is the structure of clinical trial landscape by phase related to the stress urinary incontinence market?
What is the structure of clinical trial landscape by route of administration related to the stress urinary incontinence market?
The stress urinary incontinence market has been comprehensively analyzed in IMARC's new report titled "Stress Urinary Incontinence Market: Epidemiology, Industry Trends, Share, Size, Growth, Opportunity, and Forecast 2024-2034". Stress urinary incontinence is a common condition characterized by the unintentional leakage of urine during activities that put pressure on the bladder. It occurs when the muscles and tissues that support the bladder and control the release of urine become weakened or damaged. The condition is more prevalent in women, especially those who have gone through pregnancy and childbirth, but it can also affect men. The primary symptom of the ailment is the unintentional leakage of urine, which can range from a few drops to a significant amount. Diagnosing stress urinary incontinence involves a comprehensive evaluation by a healthcare professional. The diagnostic process typically includes a thorough medical history and physical examination, where the healthcare provider may assess pelvic floor muscle strength and perform tests to reproduce SUI symptoms. Additional diagnostic procedures, such as urodynamic testing, which evaluates bladder function and measures the amount of urine leakage during various activities, may be conducted. Numerous other tests may include urine analysis to rule out infections and imaging studies to evaluate the urinary tract and pelvic organs.
The increasing cases of vaginal delivery, which can stretch and damage pelvic floor muscles, thereby compromising their ability to provide adequate support to the bladder and urethra, are primarily driving the stress urinary incontinence market. Apart from this, the rising incidences of various associated risk factors, including hormonal changes, chronic coughing, lack of regular exercise, certain connective tissue disorders like Ehlers-Danlos syndrome, prior pelvic surgery, participation in high-impact activities, etc., are also bolstering the market growth. Furthermore, the widespread adoption of estrogen creams to restore the tissue health and elasticity of the urethral tissues as well as reduce urine leakage is creating a positive outlook for the market. Besides this, the escalating utilization of pelvic floor physical therapy, which uses a variety of strategies, including manual therapy, biofeedback, electrical stimulation, etc., to help patients regain control over their pelvic floor muscles and alleviate disease symptoms, is also augmenting the market growth. Additionally, the emerging popularity of neuromodulation techniques, such as sacral nerve stimulation (SNS) and percutaneous tibial nerve stimulation (PTNS), for modulating neural signals and improving urinary control is expected to drive the stress urinary incontinence market in the coming years.
IMARC Group's new report provides an exhaustive analysis of the stress urinary incontinence market in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. This includes treatment practices, in-market, and pipeline drugs, share of individual therapies, market performance across the seven major markets, market performance of key companies and their drugs, etc. The report also provides the current and future patient pool across the seven major markets. According to the report the United States has the largest patient pool for stress urinary incontinence and also represents the largest market for its treatment. Furthermore, the current treatment practice/algorithm, market drivers, challenges, opportunities, reimbursement scenario and unmet medical needs, etc. have also been provided in the report. This report is a must-read for manufacturers, investors, business strategists, researchers, consultants, and all those who have any kind of stake or are planning to foray into the stress urinary incontinence market in any manner.
Time Period of the Study
Base Year: 2023
Historical Period: 2018-2023
Market Forecast: 2024-2034
Countries Covered
United States
Germany
France
United Kingdom
Italy
Spain
Japan
Analysis Covered Across Each Country
Historical, current, and future epidemiology scenario
Historical, current, and future performance of the stress urinary incontinence market
Historical, current, and future performance of various therapeutic categories in the market
Sales of various drugs across the stress urinary incontinence market
Reimbursement scenario in the market
In-market and pipeline drugs
Competitive Landscape:
This report also provides a detailed analysis of the current stress urinary incontinence marketed drugs and late-stage pipeline drugs.
In-Market Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
Late-Stage Pipeline Drugs
Drug Overview
Mechanism of Action
Regulatory Status
Clinical Trial Results
Drug Uptake and Market Performance
*Kindly note that the drugs in the above table only represent a partial list of marketed/pipeline drugs, and the complete list has been provided in the report.
Key Questions Answered in this Report:
Market Insights
How has the stress urinary incontinence market performed so far and how will it perform in the coming years?
What are the markets shares of various therapeutic segments in 2023 and how are they expected to perform till 2034?
What was the country-wise size of the stress urinary incontinence market across the seven major markets in 2023 and what will it look like in 2034?
What is the growth rate of the stress urinary incontinence market across the seven major markets and what will be the expected growth over the next ten years?
What are the key unmet needs in the market?
Epidemiology Insights
What is the number of prevalent cases (2018-2034) of stress urinary incontinence across the seven major markets?
What is the number of prevalent cases (2018-2034) of stress urinary incontinence by age across the seven major markets?
What is the number of prevalent cases (2018-2034) of stress urinary incontinence by gender across the seven major markets?
How many patients are diagnosed (2018-2034) with stress urinary incontinence across the seven major markets?
What is the size of the stress urinary incontinence patient pool (2018-2023) across the seven major markets?
What would be the forecasted patient pool (2024-2034) across the seven major markets?
What are the key factors driving the epidemiological trend of stress urinary incontinence?
What will be the growth rate of patients across the seven major markets?
Stress Urinary Incontinence: Current Treatment Scenario, Marketed Drugs and Emerging Therapies
What are the current marketed drugs and what are their market performance?
What are the key pipeline drugs and how are they expected to perform in the coming years?
How safe are the current marketed drugs and what are their efficacies?
How safe are the late-stage pipeline drugs and what are their efficacies?
What are the current treatment guidelines for stress urinary incontinence drugs across the seven major markets?
Who are the key companies in the market and what are their market shares?
What are the key mergers and acquisitions, licensing activities, collaborations, etc. related to the stress urinary incontinence market?
What are the key regulatory events related to the stress urinary incontinence market?
What is the structure of clinical trial landscape by status related to the stress urinary incontinence market?
What is the structure of clinical trial landscape by phase related to the stress urinary incontinence market?
What is the structure of clinical trial landscape by route of administration related to the stress urinary incontinence market?
1 PREFACE
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 STRESS URINARY INCONTINENCE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 STRESS URINARY INCONTINENCE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 STRESS URINARY INCONTINENCE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 STRESS URINARY INCONTINENCE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 STRESS URINARY INCONTINENCE - UNMET NEEDS
10 STRESS URINARY INCONTINENCE - KEY ENDPOINTS OF TREATMENT
11 STRESS URINARY INCONTINENCE - MARKETED PRODUCTS
11.1 List of Stress Urinary Incontinence Marketed Drugs Across the Top 7 Markets
11.1.1 Yentreve (Duloxetine) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 STRESS URINARY INCONTINENCE - PIPELINE DRUGS
12.1 List of Stress Urinary Incontinence Pipeline Drugs Across the Top 7 Markets
12.1.1 TAS303 - Taiho Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AMDC - Cook MyoSite
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. STRESS URINARY INCONTINENCE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. STRESS URINARY INCONTINENCE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 STRESS URINARY INCONTINENCE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Stress Urinary Incontinence - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Stress Urinary Incontinence - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Stress Urinary Incontinence - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Stress Urinary Incontinence - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Stress Urinary Incontinence - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Stress Urinary Incontinence - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Stress Urinary Incontinence - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Stress Urinary Incontinence - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Stress Urinary Incontinence - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Stress Urinary Incontinence - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Stress Urinary Incontinence - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Stress Urinary Incontinence - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Stress Urinary Incontinence - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Stress Urinary Incontinence - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Stress Urinary Incontinence - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Stress Urinary Incontinence - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Stress Urinary Incontinence - Access and Reimbursement Overview
16 STRESS URINARY INCONTINENCE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 STRESS URINARY INCONTINENCE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 STRESS URINARY INCONTINENCE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
2 SCOPE AND METHODOLOGY
2.1 Objectives of the Study
2.2 Stakeholders
2.3 Data Sources
2.3.1 Primary Sources
2.3.2 Secondary Sources
2.4 Market Estimation
2.4.1 Bottom-Up Approach
2.4.2 Top-Down Approach
2.5 Forecasting Methodology
3 EXECUTIVE SUMMARY
4 STRESS URINARY INCONTINENCE - INTRODUCTION
4.1 Overview
4.2 Regulatory Process
4.3 Epidemiology (2018-2023) and Forecast (2024-2034)
4.4 Market Overview (2018-2023) and Forecast (2024-2034)
4.5 Competitive Intelligence
5 STRESS URINARY INCONTINENCE - DISEASE OVERVIEW
5.1 Introduction
5.2 Symptoms and Diagnosis
5.3 Pathophysiology
5.4 Causes and Risk Factors
5.5 Treatment
6 PATIENT JOURNEY
7 STRESS URINARY INCONTINENCE - EPIDEMIOLOGY AND PATIENT POPULATION
7.1 Epidemiology - Key Insights
7.2 Epidemiology Scenario - Top 7 Markets
7.2.1 Epidemiology Scenario (2018-2023)
7.2.2 Epidemiology Forecast (2024-2034)
7.2.3 Epidemiology by Age (?2018-2034?)
7.2.4 Epidemiology by Gender (?2018-2034?)
7.2.5 Diagnosed Cases (?2018-2034?)
7.2.6 Patient Pool/Treated Cases (?2018-2034?)
7.3 Epidemiology Scenario - United States
7.3.1 Epidemiology Scenario (2018-2023)
7.3.2 Epidemiology Forecast (2024-2034)
7.3.3 Epidemiology by Age (?2018-2034?)
7.3.4 Epidemiology by Gender (?2018-2034?)
7.3.5 Diagnosed Cases (?2018-2034?)
7.3.6 Patient Pool/Treated Cases (?2018-2034?)
7.4 Epidemiology Scenario - Germany
7.4.1 Epidemiology Scenario (2018-2023)
7.4.2 Epidemiology Forecast (2024-2034)
7.4.3 Epidemiology by Age (?2018-2034?)
7.4.4 Epidemiology by Gender (?2018-2034?)
7.4.5 Diagnosed Cases (?2018-2034?)
7.4.6 Patient Pool/Treated Cases (?2018-2034?)
7.5 Epidemiology Scenario - France
7.5.1 Epidemiology Scenario (2018-2023)
7.5.2 Epidemiology Forecast (2024-2034)
7.5.3 Epidemiology by Age (?2018-2034?)
7.5.4 Epidemiology by Gender (?2018-2034?)
7.5.5 Diagnosed Cases (?2018-2034?)
7.5.6 Patient Pool/Treated Cases (?2018-2034?)
7.6 Epidemiology Scenario - United Kingdom
7.6.1 Epidemiology Scenario (2018-2023)
7.6.2 Epidemiology Forecast (2024-2034)
7.6.3 Epidemiology by Age (?2018-2034?)
7.6.4 Epidemiology by Gender (?2018-2034?)
7.6.5 Diagnosed Cases (?2018-2034?)
7.6.6 Patient Pool/Treated Cases (?2018-2034?)
7.7 Epidemiology Scenario - Italy
7.7.1 Epidemiology Scenario (2018-2023)
7.7.2 Epidemiology Forecast (2024-2034)
7.7.3 Epidemiology by Age (?2018-2034?)
7.7.4 Epidemiology by Gender (?2018-2034?)
7.7.5 Diagnosed Cases (?2018-2034?)
7.7.6 Patient Pool/Treated Cases (?2018-2034?)
7.8 Epidemiology Scenario - Spain
7.8.1 Epidemiology Scenario (2018-2023)
7.8.2 Epidemiology Forecast (2024-2034)
7.8.3 Epidemiology by Age (?2018-2034?)
7.8.4 Epidemiology by Gender (?2018-2034?)
7.8.5 Diagnosed Cases (?2018-2034?)
7.8.6 Patient Pool/Treated Cases (?2018-2034?)
7.9 Epidemiology Scenario - Japan
7.9.1 Epidemiology Scenario (2018-2023)
7.9.2 Epidemiology Forecast (2024-2034)
7.9.3 Epidemiology by Age (?2018-2034?)
7.9.4 Epidemiology by Gender (?2018-2034?)
7.9.5 Diagnosed Cases (?2018-2034?)
7.9.6 Patient Pool/Treated Cases (?2018-2034?)
8 STRESS URINARY INCONTINENCE - TREATMENT ALGORITHM, GUIDELINES, AND MEDICAL PRACTICES
8.1 Guidelines, Management and Treatment
8.2 Treatment Algorithm
9 STRESS URINARY INCONTINENCE - UNMET NEEDS
10 STRESS URINARY INCONTINENCE - KEY ENDPOINTS OF TREATMENT
11 STRESS URINARY INCONTINENCE - MARKETED PRODUCTS
11.1 List of Stress Urinary Incontinence Marketed Drugs Across the Top 7 Markets
11.1.1 Yentreve (Duloxetine) - Eli Lilly and Company
11.1.1.1 Drug Overview
11.1.1.2 Mechanism of Action
11.1.1.3 Regulatory Status
11.1.1.4 Clinical Trial Results
11.1.1.5 Sales Across Major Markets
Kindly note that the above only represents a partial list of marketed drugs, and the complete list has been provided in the report.
12 STRESS URINARY INCONTINENCE - PIPELINE DRUGS
12.1 List of Stress Urinary Incontinence Pipeline Drugs Across the Top 7 Markets
12.1.1 TAS303 - Taiho Pharmaceutical
12.1.1.1 Drug Overview
12.1.1.2 Mechanism of Action
12.1.1.3 Clinical Trial Results
12.1.1.4 Safety and Efficacy
12.1.1.5 Regulatory Status
12.1.2 AMDC - Cook MyoSite
12.1.2.1 Drug Overview
12.1.2.2 Mechanism of Action
12.1.2.3 Clinical Trial Results
12.1.2.4 Safety and Efficacy
12.1.2.5 Regulatory Status
Kindly note that the above only represents a partial list of pipeline drugs, and the complete list has been provided in the report.
13. STRESS URINARY INCONTINENCE - ATTRIBUTE ANALYSIS OF KEY MARKETED AND PIPELINE DRUGS
14. STRESS URINARY INCONTINENCE – CLINICAL TRIAL LANDSCAPE
14.1 Drugs by Status
14.2 Drugs by Phase
14.3 Drugs by Route of Administration
14.4 Key Regulatory Events
15 STRESS URINARY INCONTINENCE - MARKET SCENARIO
15.1 Market Scenario - Key Insights
15.2 Market Scenario - Top 7 Markets
15.2.1 Stress Urinary Incontinence - Market Size
15.2.1.1 Market Size (2018-2023)
15.2.1.2 Market Forecast (2024-2034)
15.2.2 Stress Urinary Incontinence - Market Size by Therapies
15.2.2.1 Market Size by Therapies (2018-2023)
15.2.2.2 Market Forecast by Therapies (2024-2034)
15.3 Market Scenario - United States
15.3.1 Stress Urinary Incontinence - Market Size
15.3.1.1 Market Size (2018-2023)
15.3.1.2 Market Forecast (2024-2034)
15.3.2 Stress Urinary Incontinence - Market Size by Therapies
15.3.2.1 Market Size by Therapies (2018-2023)
15.3.2.2 Market Forecast by Therapies (2024-2034)
15.3.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.4 Market Scenario - Germany
15.4.1 Stress Urinary Incontinence - Market Size
15.4.1.1 Market Size (2018-2023)
15.4.1.2 Market Forecast (2024-2034)
15.4.2 Stress Urinary Incontinence - Market Size by Therapies
15.4.2.1 Market Size by Therapies (2018-2023)
15.4.2.2 Market Forecast by Therapies (2024-2034)
15.4.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.5 Market Scenario - France
15.5.1 Stress Urinary Incontinence - Market Size
15.5.1.1 Market Size (2018-2023)
15.5.1.2 Market Forecast (2024-2034)
15.5.2 Stress Urinary Incontinence - Market Size by Therapies
15.5.2.1 Market Size by Therapies (2018-2023)
15.5.2.2 Market Forecast by Therapies (2024-2034)
15.5.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.6 Market Scenario - United Kingdom
15.6.1 Stress Urinary Incontinence - Market Size
15.6.1.1 Market Size (2018-2023)
15.6.1.2 Market Forecast (2024-2034)
15.6.2 Stress Urinary Incontinence - Market Size by Therapies
15.6.2.1 Market Size by Therapies (2018-2023)
15.6.2.2 Market Forecast by Therapies (2024-2034)
15.6.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.7 Market Scenario - Italy
15.7.1 Stress Urinary Incontinence - Market Size
15.7.1.1 Market Size (2018-2023)
15.7.1.2 Market Forecast (2024-2034)
15.7.2 Stress Urinary Incontinence - Market Size by Therapies
15.7.2.1 Market Size by Therapies (2018-2023)
15.7.2.2 Market Forecast by Therapies (2024-2034)
15.7.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.8 Market Scenario - Spain
15.8.1 Stress Urinary Incontinence - Market Size
15.8.1.1 Market Size (2018-2023)
15.8.1.2 Market Forecast (2024-2034)
15.8.2 Stress Urinary Incontinence - Market Size by Therapies
15.8.2.1 Market Size by Therapies (2018-2023)
15.8.2.2 Market Forecast by Therapies (2024-2034)
15.8.3 Stress Urinary Incontinence - Access and Reimbursement Overview
15.9 Market Scenario - Japan
15.9.1 Stress Urinary Incontinence - Market Size
15.9.1.1 Market Size (2018-2023)
15.9.1.2 Market Forecast (2024-2034)
15.9.2 Stress Urinary Incontinence - Market Size by Therapies
15.9.2.1 Market Size by Therapies (2018-2023)
15.9.2.2 Market Forecast by Therapies (2024-2034)
15.9.3 Stress Urinary Incontinence - Access and Reimbursement Overview
16 STRESS URINARY INCONTINENCE - RECENT EVENTS AND INPUTS FROM KEY OPINION LEADERS
17 STRESS URINARY INCONTINENCE MARKET - SWOT ANALYSIS
17.1 Strengths
17.2 Weaknesses
17.3 Opportunities
17.4 Threats
18 STRESS URINARY INCONTINENCE MARKET – STRATEGIC RECOMMENDATIONS
19 APPENDIX
